Servier and Precision BioSciences, a clinical stage biotechnology developing allogeneic CAR T and in vivo gene correction therapies, have added two additional hematological cancer targets and two solid tumor targets to their collaboration, for a total of four new programs.
Both partners are already developing the PBCAR0191, an investigational allogeneic chimeric antigen receptor (CAR-T) candidate targeting CD19 (for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia).
“We are pleased to add four additional targets beyond CD19 to our collaboration with Precision BioSciences as part of our commitment to oncology,” said Patrick Therasse, Deputy Head of global RD oncology at Servier. “We look forward to utilizing their genome editing platform with these new targets to potentially develop several innovative allogeneic CAR-T therapies for patients with a range of solid and hematological malignancies.”
With 700 Servier employees working each day to develop innovative therapeutic solutions in oncology, Servier intends to dedicate 50% of its global R&D budget to researching cancer treatments.